MétaCan
Menu
← Back to cohort
Record W4414078723 · doi:10.1016/j.cont.2025.101929

5 - One-Year Outcomes of the Optilume® Urethral Drug-Coated Balloon for the Treatment of Benign Prostatic Hyperplasia

2025· article· en· W4414078723 on OpenAlexaffabout
Mohannad Bitar, Omar Buksh, Naeem Bhojani, Bilal Chughtai, Kevin C. Zorn, Premal Patel, Hazem Elmansy, Malek Meskawi, Edward D. Matsumoto, Dean Elterman

Bibliographic record

VenueContinence · 2025
Typearticle
Languageen
FieldMedicine
TopicUrinary Bladder and Prostate Research
Canadian institutionsThunder Bay Regional Health Sciences CentreCentre Hospitalier de l’Université de MontréalBP (Canada)University of Toronto
Fundersnot available
KeywordsDysuriaBalloonAdverse effectBalloon dilationUrinary systemComplicationLower urinary tract symptomsGenitourinary system

Abstract

fetched live from OpenAlex

Hypothesis / aims of study The Optilume® drug-coated balloon (DCB) represents an innovative therapy for lower urinary tract symptoms (LUTS), integrating mechanical dilation for prompt symptom improvement with targeted paclitaxel delivery. This study examines the safety profile and functional outcomes of the Optilume BPH catheter system in one year. Study design, materials and methods This prospective, single-arm, multi-center, open-label study will be conducted at Canadian centers with 24 patients to evaluate the safety of the endoscopic Optilume BPH drug-coated balloon procedure for LUTS due to BPE from July 2022 to January 2025. The study will assess the complication rate at 90 days and evaluate functional outcomes at baseline, 3, 6, and 12 months. Results Out of 24 patients, 17 (70.8%) experienced a total of 42 adverse events (AEs), the majority of which were mild (Grade I: 70.8%). The most reported side effects were hematuria (41.6%), dysuria (16.6%), urinary tract infection (UTI) (8.4%), and urinary urgency (8.4%). Significant symptomatic improvement was observed over time. IPSS scores decreased from 22.5 ± 5.1 at baseline to 11 ± 6.6 at 12 months, while QoL scores improved from 4.6 ± 1.3 to 1.9 ± 1.4 over the same period. Qmax increased from 9.4 ± 3.6 mL/s to 15.7 ± 4.9 mL/s at 3 months, remaining stable at 15.3 ± 7.7 mL/s at 12 months. Post-void residual (PVR) volume decreased from 96.3 ± 83.9 mL to 68.1 ± 43.9 mL at 12 months, reflecting sustained improvements in urinary function. No significant differences were observed in sexual function scores, including IIEF, MSHQ function, and bother scores, indicating that the procedure did not negatively impact sexual health Interpretation of results The Optilume BPH drug-coated balloon procedure demonstrated significant symptomatic and functional improvements while maintaining a favorable safety profile over 12 months. Most adverse events were mild and self-limiting, with no serious complications or need for surgical intervention. Improvements in IPSS, QoL, Qmax, and PVR were sustained over time, and sexual function remained stable. Concluding message These findings support Optilume BPH as an effective and well-tolerated minimally invasive treatment for BPH-related LUTS. Funding No funding Clinical Trial Yes Registration Number The SUMMIT study RCT No Subjects Human Helsinki Yes Informed Consent Yes

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.012

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.027
GPT teacher head0.326
Teacher spread0.299 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueContinence→Same topicUrinary Bladder and Prostate Research→French-language works237,207→